Myriad Genetics stock (US62855J1043): Q1 2026 earnings miss and recent price drop

Myriad Genetics stock has faced pressure following its Q1 2026 earnings release on May 5, 2026, where the company posted an EPS of -$0.09, missing the consensus estimate of -$0.06 by $0.03, MarketBeat as of May 2026. The shares, listed on Nasdaq, dropped 4.30% on July 25, 2025, closing at $4.45 from $4.65, StockInvest.us as of July 25, 2025. Year-to-date, the stock is down 31.5% from $6.15.

As of: 12.05.2026

By the editorial team – specialized in equity coverage.

Myriad Genetics: core business model

Myriad Genetics focuses on molecular diagnostics, developing and commercializing genetic tests to assess hereditary cancer risks and guide treatment, MarketBeat as of 2026. The company offers tests like myRisk Hereditary Cancer and BRACAnalysis for BRCA1/2 mutations. Revenue stems primarily from clinical diagnostics, with a push into companion diagnostics for oncology drugs. Headquartered in Salt Lake City, Utah, Myriad serves physicians and patients across the US, where genetic testing demand grows amid precision medicine trends.

For US investors, Myriad's Nasdaq listing provides direct exposure to the expanding US genomics market, valued at billions annually per sector reports. The firm's tests integrate into US healthcare workflows, benefiting from Medicare coverage expansions for hereditary cancer screening.

Main revenue and product drivers for Myriad Genetics

Key products include myRisk, which panels 48 genes for cancer risk, and Prequel Prenatal Screen for non-invasive prenatal testing. Oncology remains the largest segment, contributing the bulk of revenue. In Q1 2026 results published May 5, 2026, the company highlighted volume growth in hereditary cancer testing despite the EPS miss, per earnings data. Pharma services, partnering with drug developers, add diversification.

Test volumes drive topline growth, with US volumes tied to screening guidelines from bodies like NCCN. Reimbursement from US payers is critical, as policy shifts impact adoption rates for Myriad's portfolio.

Industry trends and competitive position

The molecular diagnostics sector sees robust US demand, with genetic testing market projected to grow double-digits through 2030 per industry trackers. Competitors like Guardant Health and Invitae challenge Myriad, but its established BRCA franchise provides a moat. Myriad differentiates via broad panels and pharma collaborations, positioning it in the US precision oncology space.

Why Myriad Genetics matters for US investors

Myriad Genetics offers US investors access to genomics innovation, with tests reimbursable under US insurance plans. Nasdaq-traded (MYGN), it captures US healthcare spending growth, particularly in cancer care where hereditary risks affect millions. Exposure to US biopharma partnerships enhances its relevance amid domestic drug development pipelines.

Conclusion

Myriad Genetics reported a Q1 2026 earnings miss with EPS of -$0.09 versus expected -$0.06, contributing to share price declines including a 4.30% drop to $4.45 on July 25, 2025. Trading at $4.21 recently with a hold consensus and $6.40 price target, the stock reflects challenges in diagnostics execution. Investors track upcoming quarters for volume recovery and reimbursement trends in the competitive US genomics landscape.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.